- •Hematuria II: causes and investigation
- •Hematospermia
- •Lower urinary tract symptoms (LUTS)
- •Nocturia and nocturnal polyuria
- •Flank pain
- •Urinary incontinence in adults
- •Genital symptoms
- •Abdominal examination in urological disease
- •Digital rectal examination (DRE)
- •Lumps in the groin
- •Lumps in the scrotum
- •2 Urological investigations
- •Urine examination
- •Urine cytology
- •Radiological imaging of the urinary tract
- •Uses of plain abdominal radiography (KUB X-ray—kidneys, ureters, bladder)
- •Intravenous pyelography (IVP)
- •Other urological contrast studies
- •Computed tomography (CT) and magnetic resonance imaging (MRI)
- •Radioisotope imaging
- •Post-void residual urine volume measurement
- •3 Bladder outlet obstruction
- •Regulation of prostate growth and development of benign prostatic hyperplasia (BPH)
- •Pathophysiology and causes of bladder outlet obstruction (BOO) and BPH
- •Benign prostatic obstruction (BPO): symptoms and signs
- •Diagnostic tests in men with LUTS thought to be due to BPH
- •Why do men seek treatment for their symptoms?
- •Watchful waiting for uncomplicated BPH
- •Medical management of BPH: combination therapy
- •Medical management of BPH: alternative drug therapy
- •Minimally invasive management of BPH: surgical alternatives to TURP
- •Invasive surgical alternatives to TURP
- •TURP and open prostatectomy
- •Indications for and technique of urethral catheterization
- •Indications for and technique of suprapubic catheterization
- •Management of nocturia and nocturnal polyuria
- •High-pressure chronic retention (HPCR)
- •Bladder outlet obstruction and retention in women
- •Urethral stricture disease
- •4 Incontinence
- •Causes and pathophysiology
- •Evaluation
- •Treatment of sphincter weakness incontinence: injection therapy
- •Treatment of sphincter weakness incontinence: retropubic suspension
- •Treatment of sphincter weakness incontinence: pubovaginal slings
- •Overactive bladder: conventional treatment
- •Overactive bladder: options for failed conventional therapy
- •“Mixed” incontinence
- •Post-prostatectomy incontinence
- •Incontinence in the elderly patient
- •Urinary tract infection: microbiology
- •Lower urinary tract infection
- •Recurrent urinary tract infection
- •Urinary tract infection: treatment
- •Acute pyelonephritis
- •Pyonephrosis and perinephric abscess
- •Other forms of pyelonephritis
- •Chronic pyelonephritis
- •Septicemia and urosepsis
- •Fournier gangrene
- •Epididymitis and orchitis
- •Periurethral abscess
- •Prostatitis: presentation, evaluation, and treatment
- •Other prostate infections
- •Interstitial cystitis
- •Tuberculosis
- •Parasitic infections
- •HIV in urological surgery
- •6 Urological neoplasia
- •Pathology and molecular biology
- •Prostate cancer: epidemiology and etiology
- •Prostate cancer: incidence, prevalence, and mortality
- •Prostate cancer pathology: premalignant lesions
- •Counseling before prostate cancer screening
- •Prostate cancer: clinical presentation
- •PSA and prostate cancer
- •PSA derivatives: free-to-total ratio, density, and velocity
- •Prostate cancer: transrectal ultrasonography and biopsies
- •Prostate cancer staging
- •Prostate cancer grading
- •General principles of management of localized prostate cancer
- •Management of localized prostate cancer: watchful waiting and active surveillance
- •Management of localized prostate cancer: radical prostatectomy
- •Postoperative course after radical prostatectomy
- •Prostate cancer control with radical prostatectomy
- •Management of localized prostate cancer: radical external beam radiotherapy (EBRT)
- •Management of localized prostate cancer: brachytherapy (BT)
- •Management of localized and radiorecurrent prostate cancer: cryotherapy and HIFU
- •Management of locally advanced nonmetastatic prostate cancer (T3–4 N0M0)
- •Management of advanced prostate cancer: hormone therapy I
- •Management of advanced prostate cancer: hormone therapy II
- •Management of advanced prostate cancer: hormone therapy III
- •Management of advanced prostate cancer: androgen-independent/ castration-resistant disease
- •Palliative management of prostate cancer
- •Prostate cancer: prevention; complementary and alternative therapies
- •Bladder cancer: epidemiology and etiology
- •Bladder cancer: pathology and staging
- •Bladder cancer: presentation
- •Bladder cancer: diagnosis and staging
- •Muscle-invasive bladder cancer: surgical management of localized (pT2/3a) disease
- •Muscle-invasive bladder cancer: radical and palliative radiotherapy
- •Muscle-invasive bladder cancer: management of locally advanced and metastatic disease
- •Bladder cancer: urinary diversion after cystectomy
- •Transitional cell carcinoma (UC) of the renal pelvis and ureter
- •Radiological assessment of renal masses
- •Benign renal masses
- •Renal cell carcinoma: epidemiology and etiology
- •Renal cell carcinoma: pathology, staging, and prognosis
- •Renal cell carcinoma: presentation and investigations
- •Renal cell carcinoma: active surveillance
- •Renal cell carcinoma: surgical treatment I
- •Renal cell carcinoma: surgical treatment II
- •Renal cell carcinoma: management of metastatic disease
- •Testicular cancer: epidemiology and etiology
- •Testicular cancer: clinical presentation
- •Testicular cancer: serum markers
- •Testicular cancer: pathology and staging
- •Testicular cancer: prognostic staging system for metastatic germ cell cancer
- •Testicular cancer: management of non-seminomatous germ cell tumors (NSGCT)
- •Testicular cancer: management of seminoma, IGCN, and lymphoma
- •Penile neoplasia: benign, viral-related, and premalignant lesions
- •Penile cancer: epidemiology, risk factors, and pathology
- •Squamous cell carcinoma of the penis: clinical management
- •Carcinoma of the scrotum
- •Tumors of the testicular adnexa
- •Urethral cancer
- •Wilms tumor and neuroblastoma
- •7 Miscellaneous urological diseases of the kidney
- •Cystic renal disease: simple cysts
- •Cystic renal disease: calyceal diverticulum
- •Cystic renal disease: medullary sponge kidney (MSK)
- •Acquired renal cystic disease (ARCD)
- •Autosomal dominant (adult) polycystic kidney disease (ADPKD)
- •Ureteropelvic junction (UPJ) obstruction in adults
- •Anomalies of renal ascent and fusion: horseshoe kidney, pelvic kidney, malrotation
- •Renal duplications
- •8 Stone disease
- •Kidney stones: epidemiology
- •Kidney stones: types and predisposing factors
- •Kidney stones: mechanisms of formation
- •Evaluation of the stone former
- •Kidney stones: presentation and diagnosis
- •Kidney stone treatment options: watchful waiting
- •Stone fragmentation techniques: extracorporeal lithotripsy (ESWL)
- •Intracorporeal techniques of stone fragmentation (fragmentation within the body)
- •Kidney stone treatment: percutaneous nephrolithotomy (PCNL)
- •Kidney stones: open stone surgery
- •Kidney stones: medical therapy (dissolution therapy)
- •Ureteric stones: presentation
- •Ureteric stones: diagnostic radiological imaging
- •Ureteric stones: acute management
- •Ureteric stones: indications for intervention to relieve obstruction and/or remove the stone
- •Ureteric stone treatment
- •Treatment options for ureteric stones
- •Prevention of calcium oxalate stone formation
- •Bladder stones
- •Management of ureteric stones in pregnancy
- •Hydronephrosis
- •Management of ureteric strictures (other than UPJ obstruction)
- •Pathophysiology of urinary tract obstruction
- •Ureter innervation
- •10 Trauma to the urinary tract and other urological emergencies
- •Renal trauma: clinical and radiological assessment
- •Renal trauma: treatment
- •Ureteral injuries: mechanisms and diagnosis
- •Ureteral injuries: management
- •Bladder and urethral injuries associated with pelvic fractures
- •Bladder injuries
- •Posterior urethral injuries in males and urethral injuries in females
- •Anterior urethral injuries
- •Testicular injuries
- •Penile injuries
- •Torsion of the testis and testicular appendages
- •Paraphimosis
- •Malignant ureteral obstruction
- •Spinal cord and cauda equina compression
- •11 Infertility
- •Male reproductive physiology
- •Etiology and evaluation of male infertility
- •Lab investigation of male infertility
- •Oligospermia and azoospermia
- •Varicocele
- •Treatment options for male factor infertility
- •12 Disorders of erectile function, ejaculation, and seminal vesicles
- •Physiology of erection and ejaculation
- •Impotence: evaluation
- •Impotence: treatment
- •Retrograde ejaculation
- •Peyronie’s disease
- •Priapism
- •13 Neuropathic bladder
- •Innervation of the lower urinary tract (LUT)
- •Physiology of urine storage and micturition
- •Bladder and sphincter behavior in the patient with neurological disease
- •The neuropathic lower urinary tract: clinical consequences of storage and emptying problems
- •Bladder management techniques for the neuropathic patient
- •Catheters and sheaths and the neuropathic patient
- •Management of incontinence in the neuropathic patient
- •Management of recurrent urinary tract infections (UTIs) in the neuropathic patient
- •Management of hydronephrosis in the neuropathic patient
- •Bladder dysfunction in multiple sclerosis, in Parkinson disease, after stroke, and in other neurological disease
- •Neuromodulation in lower urinary tract dysfunction
- •14 Urological problems in pregnancy
- •Physiological and anatomical changes in the urinary tract
- •Urinary tract infection (UTI)
- •Hydronephrosis
- •15 Pediatric urology
- •Embryology: urinary tract
- •Undescended testes
- •Urinary tract infection (UTI)
- •Ectopic ureter
- •Ureterocele
- •Ureteropelvic junction (UPJ) obstruction
- •Hypospadias
- •Normal sexual differentiation
- •Abnormal sexual differentiation
- •Cystic kidney disease
- •Exstrophy
- •Epispadias
- •Posterior urethral valves
- •Non-neurogenic voiding dysfunction
- •Nocturnal enuresis
- •16 Urological surgery and equipment
- •Preparation of the patient for urological surgery
- •Antibiotic prophylaxis in urological surgery
- •Complications of surgery in general: DVT and PE
- •Fluid balance and management of shock in the surgical patient
- •Patient safety in the operating room
- •Transurethral resection (TUR) syndrome
- •Catheters and drains in urological surgery
- •Guide wires
- •JJ stents
- •Lasers in urological surgery
- •Diathermy
- •Sterilization of urological equipment
- •Telescopes and light sources in urological endoscopy
- •Consent: general principles
- •Cystoscopy
- •Transurethral resection of the prostate (TURP)
- •Transurethral resection of bladder tumor (TURBT)
- •Optical urethrotomy
- •Circumcision
- •Hydrocele and epididymal cyst removal
- •Nesbit procedure
- •Vasectomy and vasovasostomy
- •Orchiectomy
- •Urological incisions
- •JJ stent insertion
- •Nephrectomy and nephroureterectomy
- •Radical prostatectomy
- •Radical cystectomy
- •Ileal conduit
- •Percutaneous nephrolithotomy (PCNL)
- •Ureteroscopes and ureteroscopy
- •Pyeloplasty
- •Laparoscopic surgery
- •Endoscopic cystolitholapaxy and (open) cystolithotomy
- •Scrotal exploration for torsion and orchiopexy
- •17 Basic science of relevance to urological practice
- •Physiology of bladder and urethra
- •Renal anatomy: renal blood flow and renal function
- •Renal physiology: regulation of water balance
- •Renal physiology: regulation of sodium and potassium excretion
- •Renal physiology: acid–base balance
- •18 Urological eponyms
- •Index
580 CHAPTER 16 Urological surgery and equipment
Fluid balance and management of shock in the surgical patient
Daily fluid requirement
This can be calculated according to patient weight:
•For the first 10 kg: 100 mL/kg per 24 hours (= 1000 mL)
•For the next 10 kg (i.e., 10–20 kg): 50 mL/kg per 24 hours (= 500 mL)
•For every kg above 20 kg: 20 mL/kg per 24 hours (= 1000 mL for a patient weighing 70 kg).
Thus, for every 24 hours, a 70 kg adult will require 1000 mL for their first 10 kg of weight, plus 500 mL for their next 10 kg of weight, and 1000 mL for their last 50 kg of weight = total 24-hour fluid requirement, 2500 mL.
Daily sodium requirement is ~100 mmol, and for potassium, 770 mmol. Thus, a standard 24-hour fluid regimen is 2 L of 5% dextrose + 1 L of normal saline (equivalent to about 150 mmol Na+), with 20 mmol K+ for every liter of infused fluid.
Fluid losses from drains or nasogastric aspirate are similar in composition to plasma and should be replaced principally with normal saline.
Shock due to blood loss
Inadequate organ perfusion and tissue oxygenation occur. The causes are hypovolemia, cardiogenic, septic, anaphylactic, and neurogenic. The most common cause in the surgical patient is hypovolemia due to blood and other fluid loss. Hemorrhage is an acute loss of circulating blood volume.
Hemorrhagic shock may be classified as follows:
•Class I: up to 750 mL of blood loss (15% of blood volume); normal pulse rate (PR), respiratory rate (RR), blood pressure (BP), urine output, and mental status
•Class II: 750–1500 mL (15–30% of blood volume); PR >100; decreased pulse pressure due to increased diastolic pressure; RR 20–30; urinary output 20–30 mL/hr
•Class III: 1500–2000 mL (30–40% of blood volume); PR >120; decreased BP and pulse pressure due to decreased systolic pressure; RR 30–40; urine output 5–15 mL/hr; confusion
•Class IV: >2000 mL (>40% of blood volume); PR >140; decreased pulse pressure and BP; RR >35; urine output <5 mL/hr; cold, clammy skin
Management
•Remember ABC (Airway, Breathing, Circulation): 100% oxygen to improve tissue oxygenation
•ECG, cardiac monitor, pulse oximetry
•Insert two short and wide IV cannulae in the antecubital fossa (e.g., 16G). A central venous line may be required.
•Infuse 1 L of warm Hartmann’s solution or, if severe hemorrhage, then start a colloid instead. Aim for a urinary output of 0.5 mL/kg/hr and maintenance of blood pressure.
FLUID BALANCE AND MANAGEMENT OF SHOCK 581
•Check complete blood count (CBC), coagulation screen, and cardiac enzymes.
•Cross-match 6 units of blood.
•Obtain arterial blood gases (ABG) to assess oxygenation and pH.
Obvious and excessive blood loss may be seen from drains, but drains can also block, so assume there is covert bleeding if there is a tachycardia (and low blood pressure).
If this regimen fails to stabilize pulse and blood pressure, return the patient to the operating room for exploratory surgery.
Further reading
American College of Surgeons Committee on Trauma (1999). Advanced Trauma Life Support for Doctors—Student Course Manual, 6th Edition.
582 CHAPTER 16 Urological surgery and equipment
Patient safety in the operating room
It is a fundamental part of safe surgical practice to cross-check that the following have been done prior to starting an operation or procedure. The process of cross-checking should be done with another member of staff (time out).
•Patient identification. Confirm that you are operating on the right patient by a process of active identification (i.e., ask the patient their name, date of birth, and their address to confirm that you are talking to the correct patient).
•Ensure you are doing the correct procedure and on the correct side by cross-checking with the notes and X-rays. For lateralized procedures (e.g., nephrectomy, PCNL), the correct side of the
operation should be confirmed by cross-checking with the X-rays and with the X-ray report, as well as referring to the notes. Where it is possible for the sides of an IVP to be incorrectly labeled, this cannot happen with a CT scan, where the location of the liver (right side) and the spleen (left side) provide confirmation of what side is what. In addition, the patient should have the correct side mark on their body by the operating surgical team in the holding area.
•Check that appropriate antibiotic prophylaxis has been given.
•Check that DVT prophylaxis has been administered (e.g., heparin, AK-TEDS, intermittent pneumatic compression boots).
•Ensure that blood is available, if appropriate.
•The patient should be safely and securely positioned on the operating table—pressure points are padded, not touching metal (to avoid diathermy burns), body straps are securely in place.
Develop an approach to operating that involves members of your team. Listen to the opinions of staff members who are junior to you. They may sometimes be able to identify errors that are not obvious to you.
Cultivate the respect of the recovery room staff. They may express concern about a patient under their care—listen to their concerns, take them seriously, and, if all is well, reassure them.
It does no harm to your patients or to your reputation for you to develop the habit of visiting every patient in the recovery room in order to check that all is well. You may be able to identify a problem before it has developed into a crisis, and, at the very least, you will gain a reputation for being a caring surgeon.
TRANSURETHRAL RESECTION (TUR) SYNDROME 583
Transurethral resection (TUR) syndrome
TUR syndrome arises from the infusion of a large volume of hypotonic irrigating solution into the circulation during endoscopic procedures (e.g., TURP, TURBT, PCNL). It occurs in 0.5% of TURPs.
Pathophysiology
Biochemical, hemodynamic, and neurological disturbances occur:
•Dilutional hyponatremia is the most important—and serious—factor leading to the symptoms and signs. The serum sodium usually has to fall to <125 mmol/L before the patient becomes unwell.
•Hypertension is due to fluid overload.
•Visual disturbances may be due to the fact that glycine is a neurotransmitter in the retina.
Diagnosis—symptoms, signs, and tests
These include confusion, nausea, vomiting, hypertension, bradycardia and visual disturbances, and seizures. If the patient is awake (spinal anesthesia), they may report visual disturbances (e.g., flashing lights).
Preventing development of TUR syndrome and definitive treatment
Use a continuous irrigating cystoscope (provides low-pressure irrigation), limit resection time, avoid aggressive resection near the capsule, and reduce the height of the irrigant solution.1
For prolonged procedures, where a greater degree of fluid absorption may occur, measure serum Na and give 20–40 mg of IV furosemide to start off-loading the excess fluid that has been absorbed. If the serum sodium comes back as being normal, you will have done little harm by giving the furosemide, but if it comes back at <125mmol/L, you will have started treatment already and thereby may have prevented the development of severe TUR syndrome.
Techniques for measuring fluid overload (not commonly done)
•Weighing machines can be added to the ordinary operating table.2
•Adding a little alcohol to the irrigating fluid and constantly monitoring the expired air with a breathalyser3 allows an estimation of the volume of excess fluid that has been absorbed.
1 Madsen PO, Naber KG (1973). The importance of the pressure in the prostatic fossa and absorption of irrigating fluid during transurethral resection of the prostate. J Urol 109:446–452.
2 Coppinger SW, Lewis CA, Milroy EJG (1995). A method of measuring fluid balance during transurethral resection of the prostate. Br J Urol 76:66–72.
3 Hahn RG (1993). Ethanol monitoring of extravascular absorption of irrigating fluid. Br J Urol 72:766–769.